OncoMatch/Clinical Trials/NCT06090994
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
Is NCT06090994 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Huaier granule and Capecitabine for colorectal cancer.
Treatment: Huaier granule · Capecitabine — This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage Ⅱ (TNM)
TNM stage Ⅱ
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — radical resection (R0)
Received radical resection of colorectal cancer (R0) within 12 weeks prior to enrollment.
Cannot have received: neoadjuvant therapy
Not receiving neoadjuvant therapy before surgery
Cannot have received: adjuvant therapy
not receiving any adjuvant therapy after surgery
Cannot have received: Huaier granules or traditional Chinese patent medicines and simple preparations with similar efficacy or indications (Huaier granules, compound cantharides capsules, cinobufacin capsules, Kangai injection, Pingxiao tablets)
In the past one month, the subjects have received Huaier granules or traditional Chinese patent medicines and simple preparations with similar efficacy or indications to Huaier granules (such as compound cantharides capsules, cinobufacin capsules, Kangai injection, Pingxiao tablets, please refer to the instruction manual for details).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify